Skip to main content
Premium Trial:

Request an Annual Quote

Universal Diagnostic Laboratories to Market Combimatrix Miscarriage Test in California

NEW YORK (GenomeWeb) – CombiMatrix said today that it has made an agreement with Universal Diagnostic Laboratories under which the lab will market and distribute CombiMatrix's chromosomal microarray miscarriage analysis test in California.

Specific terms of the deal were not disclosed. 

In a statement, CombiMatrix President and CEO Mark McDonough said that the move will make the company's test more accessible to women in California who experience recurrent pregnancy loss and hope to be able to identify or rule out a genetic cause. UDL President and CEO Michael Mosunic added that his company's interest in the CombiMatrix miscarriage test was based on demonstration of the superior diagnostic abilities of chromosomal microarray analysis over karyotyping in this area of medicine. 

CombiMatrix researchers published a study in June in Genetics in Medicine showing that the company's microarray analysis of more than 8,000 miscarriage samples yielded successful results more than 90 percent of the time, a significantly better performance than standard karyotyping approaches, which are known to fail up to 40 percent of the time.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.